BehanFM, IorioF, PiccoG, et al.Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature, 2019; 568:511–516. DOI: 10.1038/s41586-019-1103-9.
3.
HartT, ChandrashekharM, AreggerM, et al.High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell, 2015; 163:1515–1526. DOI: 10.1016/j.cell.2015.11.015.
4.
MeyersRM, BryanJG, McFarlandJM, et al.Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet, 2017; 49:1779–1784. DOI: 10.1038/ng.3984.
5.
ShiJ, WangE, MilazzoJP, et al.Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol, 2015; 33:661–667. DOI: 10.1038/nbt.3235.
6.
TzelepisK, Koike-YusaH, De BraekeleerE, et al.A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep, 2016; 17:1193–1205. DOI: 10.1016/j.celrep.2016.09.079.
7.
WangT, YuH, HughesNW, et al.Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell, 2017; 168:890–903.e15. DOI: 10.1016/j.cell.2017.01.013.
8.
DepMap at Broad Institute. Cancer dependency map. Available online at: https://depmap.org/portal/ (last accessed January28, 2020).
DempsterJM, PaciniC, PantelS, et al.Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun, 2019; 10:5817. DOI: 10.1038/s41467-019-13805-y.
11.
JohnsonWE, LiC, RabinovicA. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics, 2007; 8:118–127. DOI: 10.1093/biostatistics/kxj037.
12.
TsherniakA, VazquezF, MontgomeryPG, et al.Defining a cancer dependency map. Cell, 2017; 170:564–576.e16. DOI: 10.1016/j.cell.2017.06.010.
